There are two new promising drugs that could tentatively treat Alzheimer’s: Leqembi (from biotech firms Eisai and Biogen) and an experimental treatment developed by Eli Lilly (LLY.N), donanemab. They work by removing a dangerous protein called beta amyloid from the brain that affects the 6.5 million Americans who are…